LONGEVA.

Ac-SDKP: adverse events and evidence limits

Ac-SDKP is the tetrapeptide Ac-Ser-Asp-Lys-Pro. In Lenfant and colleagues’ study, natural and synthetic peptide prevented mouse hematopoietic stem cells from entering DNA synthesis after cytarabine. This is an experimental effect on hematopoiesis, not a patient adverse-reaction frequency. [1]

The abstract gives neither the administration route nor clinical reaction frequencies. It establishes neither human safety nor the effects of full-length thymosin β4. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Prevention of hematopoietic stem cells entering DNA synthesisMouse hematopoietic stem cells, after cytarabineAn experimental effect on hematopoiesis; the abstract gives neither the administration route nor clinical reaction frequencies[1]

References

  1. Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. (1989). Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure https://doi.org/10.1073/pnas.86.3.779.